Outcomes of allogeneic hematopoietic stem cell transplantation for ATL with HTLV-1 antibody positive donors: Allo-HCT for ATL from HTLV-1 antibody positive donors.
Allogeneic hematopoietic stem cell transplantation (allo-HCT) is the only available curative treatment option for patients with aggressive adult T cell leukemia-lymphoma (ATL). Donor human T cell leukemia virus (HTLV)-1 seropositivity is a critical concern when choosing relative donors, as they are not usually recommended due solely to the occurrence of donor-derived ATL. A previous report suggested that allo-HCT with an HTLV-1-seropositive donor increased ATL-related mortality. We updated the risk assessment for choosing an HTLV-1-seropositive allo-HCT donor for ATL. Our current registry data, which include larger numbers of HTLV-1-seropositive donors and longer observation periods, revealed no significant difference in overall survival [hazard ratio (HR): 0.93, 95% confidence interval (CI): 0.70‒1.24; P = 0.61) or cumulative incidence of either ATL-related (HR: 0.96, 95% CI: 0.64‒1.45; P = 0.80) or non-ATL-related mortality (HR: 0.91, 95% CI: 0.61‒1.37; P = 0.66). Similarly, when considering only ATL patients in complete remission, there was no significant difference in overall survival (HR: 1.02, 95% CI: 0.70‒1.49; P = 0.91) or cumulative incidence of either ATL-related (HR: 1.20, 95% CI: 0.66‒2.20; P=0.54) or non-ATL-related mortality (HR: 0.86, 95% CI: 0.52-1.42; P = 0.66). These data indicate that selecting HTLV-1-seropositive donors might not be contraindicated for patients with ATL receiving allo-HCT if alternative donors are unavailable. Further risk assessment remains to be performed.